GlassScriptPhysician profile
Cara G Hartle
NPI 1992948673
$2,025.89
in general payments reported to CMS, 2019-2025
28 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $311 · 2021: $203 · 2022: $35.49 · 2023: $206 · 2024: $413 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $927.35 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $340.78 | 2019-2025 | |
| Exeltis, USA INC. | $239.90 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $206.58 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $152.98 | 2019-2025 | |
| Daiichi Sankyo INC. | $138.87 | 2019-2025 | Injectafer |
| Pfizer INC. | $133.52 | 2019-2024 | |
| Lupin INC. | $122.67 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $102.83 | 2023-2024 | Gemtesa, Myfembree |
| Hologic Sales and Service, LLC | $83.89 | 2021-2024 | Aptima |
| Millicent US INC | $61.73 | 2025 | Femring, Intrarosa |
| Merck Sharp & Dohme LLC | $52.84 | 2019-2024 | Gardasil 9, Gardasil |
| Biogen, INC. | $45.48 | 2024-2025 | Zurzuvae |
| Organon LLC | $42.70 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $37.93 | 2025 | |
| Coopersurgical, INC. | $36.47 | 2024 | Paragard T 380a |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $34.18 | 2023-2025 | |
| Shield Therapeutics INC | $26.63 | 2023 | Accrufer |
| Medicem INC. | $23.15 | 2021 | |
| Astellas Pharma Global Development | $22.06 | 2024 | Veozah |
| Allergan, INC. | $16.44 | 2019 | |
| Radius Health, INC. | $14.48 | 2019 | |
| Myovant Sciences INC. | $13.96 | 2021 | |
| Avion Pharmaceuticals | $13.72 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $13.62 | 2019 | |
| Agile Therapeutics, INC. | $12.49 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.34 | 2020 | |
| Covidien LP | $12.03 | 2019 | |
| Currax Pharmaceuticals LLC | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Hartle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.